To determine whether phlebotomy to an iron depleted state improves response of chronic hepatitis C infection to alpha-interferon therapy in patients who have previously failed such therapy. A secondary objective will be to correlate iron reduction therapy via phlebotomy with hepatic iron concentration. The primary efficacy endpoints are the response rate (based on loss of hepatitis C RNA in serum) at the end of a 6-12 month course of interferon, and the ability to sustain that response for 6 months after the end of therapy.
Showing the most recent 10 out of 563 publications